Nuvig Therapeutics is a clinical-stage biotechnology company that is advancing an innovative and transformational pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. The Company's lead investigational drug candidate, NVG-2089, is an engineered Fc fragment designed to precisely target type II Fc receptors. When NVG-2089 binds to its target, it upregulates the expression of FcγRIIb and causes the expansion of T regulatory cells and the downregulation of numerous inflammatory pathways. Nuvig is based in Menlo Park, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/24 | $161,000,000 | Series B |
abrdn Alexandria Venture Investments B Capital Blue Owl  Bristol Myers Squibb Digitalis Ventures Global BioAccess Fund Leaps by Bayer LOTTE Holdings Mission BioCapital Norwest Venture Partners Novo Holdings Platanus Sanofi Ventures | undisclosed |
